IL6 and colonic neoplasm: Nakamura et al. showed that administration of ARB to colon cancer-bearing mice induced the expansion of cancer-specific CTLs and reduced the levels of immune-suppressive cytokines, interleukin-6 (IL-6), IL-10, vascular endothelial cell factor, and arginase in the tumor microenvironment [39].